[Effect of corticosteroids, quinacrine and L-652, 731 on experimental aggregation of polymorphonuclear leukocytes induced by complement and platelet activating factor (PAF)].
The effects of 6-methylprednisolone sodium succinate, quinacrine and the synthetic anti-PAF compound L-652,731 were studied on the PAF and complement induced aggregation of rabbit polymorphonuclear leukocytes in vivo. High doses (100-250 mg/kg) of corticosteroid were able to abrogate PAF and complement induced aggregation. Quinacrine (1.25 mg/kg), and L-652,731, partially precluded complement-depending aggregation. The L-652,731 dose employed was just enough to prevent PAF induced aggregation. These results suggest that in those pathological conditions in which polymorphonuclear aggregation occurs, factors other than those derived from plasmatic complement system activation, and laboring jointly with it, may be involved.
Romero
A
A
Cátedra de Patología y Clínica Médicas I, Hospital Clínico Universitario Virgen Macarena, Sevilla, España.
Muniain
M A
MA
Mata
R
R
Pozuelo
F
F
Pérez
J J
JJ
Rodríguez
M C
MC
Rodríguez
M D
MD
D000380:Agranulocytosis / Q000139:chemically induced*; D000818:Animals; D002449:Cell Aggregation / Q000187:drug effects; D003165:Complement System Proteins; D005663:Furans / Q000494:pharmacology*; D008775:Methylprednisolone / Q000031:analogs & derivatives*; D008776:Methylprednisolone Hemisuccinate / Q000494:pharmacology*; D009503:Neutropenia / Q000139:chemically induced*; D010972:Platelet Activating Factor; D011796:Quinacrine / Q000494:pharmacology*; D011817:Rabbits; D015054:Zymosan / Q000494:pharmacology*
D005663:Furans; D010972:Platelet Activating Factor; D008776:Methylprednisolone Hemisuccinate; D003165:Complement System Proteins; D015054:Zymosan; C047504:2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran; D011796:Quinacrine; D008775:Methylprednisolone
Efecto de los corticosteroides, de la quinacrina y del L-652,731 sobre la agregación experimental de los polimorfonucleares inducida por el complemento y FAP.